Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $29.14 Consensus PT from Analysts

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has earned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $29.14.

Several research firms recently commented on BCYC. Stephens reaffirmed an "equal weight" rating and set a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "buy" rating and set a $30.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, April 9th.

Bicycle Therapeutics Trading Down 0.2 %

NASDAQ BCYC traded down $0.02 on Friday, hitting $8.66. 46,042 shares of the company's stock traded hands, compared to its average volume of 395,804. The firm's 50-day moving average price is $9.23 and its two-hundred day moving average price is $15.32. The firm has a market capitalization of $598.94 million, a PE ratio of -2.63 and a beta of 1.40. Bicycle Therapeutics has a 1-year low of $6.10 and a 1-year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm's quarterly revenue was down 30.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.16) earnings per share. On average, research analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently modified their holdings of BCYC. Principal Financial Group Inc. purchased a new position in Bicycle Therapeutics in the 3rd quarter valued at about $10,028,000. State Street Corp lifted its position in shares of Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company's stock valued at $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Bicycle Therapeutics by 35.7% in the third quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock worth $457,000 after acquiring an additional 5,310 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after purchasing an additional 1,782 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new position in Bicycle Therapeutics in the 4th quarter valued at $614,000. Institutional investors and hedge funds own 86.15% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.